Skip to main content

Charles River Laboratories International, Inc. (CRL)

NYSE: CRL · IEX Real-Time Price · USD
418.01
-5.81 (-1.37%)
After-hours:Oct 25, 2021 6:31 PM EDT
423.82
3.21 (0.76%)
At close: Oct 25, 4:00 PM
Market Cap21.39B
Revenue (ttm)3.27B
Net Income (ttm)396.08M
Shares Out50.30M
EPS (ttm)7.74
PE Ratio54.73
Forward PE35.71
Dividendn/a
Ex-Dividend Daten/a
Volume231,341
Open421.00
Previous Close420.61
Day's Range417.88 - 424.77
52-Week Range219.79 - 460.21
Beta1.15
AnalystsBuy
Price Target449.18 (+6.0%)
Est. Earnings DateNov 3, 2021

About CRL

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services ...

IndustryLife Sciences Tools & Services
IPO DateJun 23, 2000
CEOJames Foster
Employees18,400
Stock ExchangeNYSE
Ticker SymbolCRL
Full Company Profile

Financial Performance

In 2020, CRL's revenue was $2.92 billion, an increase of 11.55% compared to the previous year's $2.62 billion. Earnings were $364.30 million, an increase of 44.55%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is 449.18, which is an increase of 5.98% from the latest price.

Price Target
$449.18
(5.98% upside)
Analyst Consensus: Buy

News

Charles River Laboratories Plans to Increase CRADL Capacity in Cambridge

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands CRADL facilities in Cambridge, including growth of Binney Street site and the addition of a location on Bent Street.

5 days ago - Business Wire

Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact

Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.

6 days ago - Zacks Investment Research

Charles River and ATEM Structural Discovery Announce Strategic Partnership to Provide Clients with Cryo-EM Capabilities

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #HealthcareCollabReport--Charles River Laboratories International, Inc. (NYSE: CRL) and ATEM Structural Discovery (ATEM) today announced the formation of a st...

1 week ago - Business Wire

Charles River Laboratories Schedules Third-Quarter 2021 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #3Q2021--Charles River Laboratories schedules Third-Quarter 2021 earnings release and conference call

1 week ago - Business Wire

Charles River Laboratories Announces Two Divestitures

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories announces two divestitures.

1 week ago - Business Wire

Charles River (CRAI) Stock Up 106.1% Year to Date: Here's Why

Consecutive better-than-expected top- and bottom-line performances, and an encouraging 2021 guidance have been aiding Charles River (CRAI) stock.

Other symbols:CRAI
2 weeks ago - Zacks Investment Research

Charles River Launches First Annual Healthcare Collaboration Report

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #HealthcareCollabReport--The Healthcare Collaboration Report polled more than 1,500 Americans about the current state of healthcare, drug development, and pan...

1 month ago - Business Wire

Here's Why You Should Invest in Charles River (CRL) Now

Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.

1 month ago - Zacks Investment Research

6 Reasons Why You Should Bet on Charles River (CRAI) Stock

Business diversification and investor-friendly moves aid Charles River (CRAI) stock.

Other symbols:CRAI
1 month ago - Zacks Investment Research

Charles River Laboratories to Participate in September Investor Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to participate in September Investor Conferences

1 month ago - Business Wire

Why Is Charles River (CRL) Up 9.5% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Why Charles River (CRAI) Stock Might be a Great Pick

Charles River (CRAI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Other symbols:CRAI
1 month ago - Zacks Investment Research

These Top Stocks Are Leading The S&P 500 To New Highs In 2021

Shares of vaccine-maker Moderna have skyrocketed more than 270% this year.

Other symbols:DVNFTNTITMRNAMRONUE
1 month ago - Forbes

Charles River (CRA) Hires New Energy Practice Senior Consultant

Charles River (CRAI) welcomes Randel R. Young to the position of senior consultantat its Energy Practice.

2 months ago - Zacks Investment Research

You Won't Believe the Risk This Healthcare Company Faces

It's older than the dinosaurs.

Other symbols:MRNA
2 months ago - The Motley Fool

Charles River (CRL) at a 52-Week High: What's Driving It?

Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.

2 months ago - Zacks Investment Research

MODV or CRL: Which Is the Better Value Stock Right Now?

MODV vs. CRL: Which Stock Is the Better Value Option?

Other symbols:MODV
2 months ago - Zacks Investment Research

Charles River (CRAI) Stock Up 5.7% Since Q2 Earnings Beat

Charles River (CRAI) second-quarter 2021 earnings and revenues increase year over year.

Other symbols:CRAI
2 months ago - Zacks Investment Research

Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up

Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.

2 months ago - Zacks Investment Research

Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

Charles River (CRL) delivered earnings and revenue surprises of 9.21% and 5.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Charles River Q2 Earnings

Shares of Charles River (NYSE:CRL) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 65.19% year over year to $2.61, which beat the estimate of $2.38.

2 months ago - Benzinga

Charles River Laboratories Announces Second-Quarter 2021 Results

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #2Q2021--Charles River Laboratories Announces Second-Quarter 2021 Results

2 months ago - Business Wire

Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand

Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.

2 months ago - Zacks Investment Research

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Charles River Laboratories Schedules Second-Quarter 2021 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #2Q2021--Charles River Laboratories schedules second-quarter 2021 earnings release and conference call

3 months ago - Business Wire